In the field of AD research, the most relevant steps toward CSF-to-plasma shift include Simoa measurement of both classical (Aβ42, Aβ40, p-tau181, p-tau217, p-tau231, and total tau) as well as emerging, complementary (NfL, GFAP) biomarkers in plasma (113). This evidence concerns the gene MAPT and Alzheimer disease.